Chicken infectious anemia: emerging viral disease of poultry —an overview

AbstractDue to the emerging status of chicken infectious anemia in Africa and its similarity to infectious bursal disease, it was necessary to review this disease. Chicken infectious anemia (CIA) is an immunosuppressive pathogen and thus, causes great economic losses to the poultry industry. It is caused by chicken infectious anemia virus (CIAV), a member of the genusGyrovirus, and it primarily affects progenitor cells of erythroid and myeloid series. The disease is characterized by aplastic anemia, atrophy of the thymus, and immunosuppression. It is transmitted horizontally and vertically, and chicken is considered to be the natural host. Chicken infectious anemia can be diagnosed by virus isolation and detection and serology including enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), immunoperoxidase tests, and virus neutralization test (VNT). The control measures for CIA included vaccination and good poultry health and management practices.
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

The objective of the current study was to elucidate differences between the molecular mechanisms underlying FA and AA as well as to identify biomarkers and pathways associated with FA via bioinformatics analyses. Proteomic data were obtained from bone marrow samples of patients with FA and AA. Gene ontology analysis was performed using a Database for Annotation, Visualization and Integrated Discovery. KEGG pathway enrichment analyses were conducted using the ClueGO plug-in in Cytoscape. A DEP-associated protein-protein interaction (PPI) network was constructed using STRING and visualized in Cytoscape. A total of 114 DEPs, ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
ConclusionWe suggest a one ‐compartment population model with first‐order elimination to capture the pharmacokinetic profile for basiliximab for this patient population.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
our R PMID: 31727769 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
The treatment of choice for paediatric severe aplastic anaemia (SAA) is currently a human leucocyte antigen (HLA) matched sibling donor (MSD) transplant, with 2-5 year overall survival of 82-92% [1 –4]. Historically, immunosuppressive therapy (IST) was given to those who lacked a MSD but matched unrelated donor (MUD) transplant is now considered an alternative upfront treatment if a donor can be found quickly [2]. This change partly reflects excellent results from alternative donor transplan ts but also lack of consistent long-term remission for those treated with IST alone [5–7].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Source: ClinicoEconomics and Outcomes Research - Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Cristian Vergallo, Giulia Torrieri, Riccardo Provenzani, Sini Miettinen, Karina Moslova, Markku Varjosalo, Maria Chiara Cristiano, Massimo Fresta, Christian Celia, Hélder A. Santos, Felisa Cilurzo, Luisa Di MarzioAbstractStanozolol (STZ) is a drug used to treat serious disorders like aplastic anemia and hereditary angioedema. It is also indicated as an adjunct therapy for the treatment of vascular disorders and growth failures. Encouraging results obtained using animal models demonstrated that STZ increases bon...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
The evolution of Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) as a treatment modality has witnessed the cure of several haematological conditions such as leukaemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassaemia and aplastic anaemia [1]. The many advances made in this domain, and the availability of excellent post transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease-free at five years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
This study evaluated healthcare resource utilization (HCRU), and direct costs among severe aplastic anemia (SAA) patients treated with eltrombopag (EPAG) using US claims data.Methods: This retrospective, real-world claims database study identified SAA patients aged ≥2 years treated with EPAG who initiated any SAA treatment between July 1, 2014 and December 31, 2017 (identification period) using the Truven MarketScan® databases. A subset of 82 patients treated with EPAG during the identification period were evaluated for all-cause and SAA-related HCRU and direct costs as well as blood transfusion one month before EPA...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
In this study, the abnormal PNH clones were detected using a single tube FLAER based testing and two tubes non-FLAER based testing in all cases of PNH (n = 12), healthy subjects (n = 18) and AA/MDS with PNH clone (n = 9) and compared with clinical and laboratory features at di agnosis. The receiver operator curve (ROC) analysis defined the optimal cut-offs for FLAER in granulocytes (>  0.7%) and monocytes (>  0.9%). There was significant positive correlation between FLAER and non-FLAER based testing in these cells (r >  0.3 andp 
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been successfully used for stem cell mobilization and T cell immune tolerance induction. The establishment of G-CSF-primed unmanipulated haploidentical blood and marrow transplantation (The Beijing Protocol) has achieved outcomes for the treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia with haploidentical allografts comparable to those of human leukocyte antigen (HLA)-matched sibling donor transplantation. Currently, G-CSF-mobilized bone marrow and/or peripheral blood stem cell sources have been widely used ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: African Health | Anemia | Aplastic Anemia | Pathology | Vaccines